The results of our previous study, published in 2022, suggested no relationship between the ADRB3:rs4994 polymorphism and the response of Polish female OAB patients to a single intra-detrusor BoNT/A injection, three months post-injection (response measured as absolute and relative changes in OAB symptom frequency or with scores for ICIQ-LUTS-QoL (International Consultation Incontinence Questionnaire-Lower Urinary Tract Symptoms-Quality of Life) and ICIQ-OAB (International Consultation on Incontinence Questionnaire-Overactive Bladder) questionnaires [27]. This evidence concerns the gene ADRB3 and overactive bladder.